Los Angeles Capital Management
ZVRA icon

Los Angeles Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Los Angeles Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-54,454
Closed -$552K – 2631
2025
Q4 		$552K Sell
54,454
-4,086
-7% -$38.6K ﹤0.01% 850
2025
Q3 		$557K Sell
58,540
-62,685
-52% -$629K ﹤0.01% 902
2025
Q2 		$1.07M Buy
+121,225
New +$984K ﹤0.01% 620

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Los Angeles Capital Management's ZVRA Position: Q1 2026 in Review

Los Angeles Capital Management sold out of Zevra Therapeutics (ZVRA) in Q1 2026, closing a stake of 54,454 shares — an estimated $552K sold.

Los Angeles Capital Management first reported a position in ZVRA in Q2 2025 and held it in 3 quarters. The position peaked at $1.07M in Q2 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Los Angeles Capital Management reported no remaining Zevra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Los Angeles Capital Management sold 54,454 Zevra Therapeutics shares in Q1 2026, an estimated $552K.
  • Los Angeles Capital Management first reported a position in Zevra Therapeutics in Q2 2025 and held it in 3 quarters.
  • Los Angeles Capital Management's Zevra Therapeutics position peaked at $1.07M in Q2 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.